Biopharmaceutical company Merck Serono won two awards for its Fertility Family of Pens yesterday, June 10th, which recognise its commitment to developing innovative drug delivery devices with convenience and reliability.
Merck Serono wins two Red Dot Design awards for their Fertility Family of Pens
The pens are used in fertility treatment to inject hormones for follicle stimulation, helping women and couples realise their dream of having a baby.
One of these essential hormones to treat infertility is Gonal-f, a recombinant human follicle-stimulating hormone which is prescribed to supplement or replace naturally occurring FSH in woman undergoing assisted reproductive technology. Merck’s Serono’s Family of Pens is the first pre-filled, ready-to-use set of injection devices for fertility treatment. It is based on healthcare professionals’ and patients’ feedback to provide a common injection platform for Merck Serono’s gonadotropins.
Meeta Gulyani, Head of Global Strategy and Franchises at Merck Serono said: “Winning two Red Dot Awards for our Family of Pens is a remarkable achievement for Merck Serono which acknowledges our dedication and attention to detail in designing these innovative drug delivery devices to meet the needs of the patients. Bringing to life our motto ‘As One for Patients’, developing these products was a collaborative process involving, Merck Serono’s business as well as medical device experts and out manufacturing partner the company Haselmeier. Receiving the Red Dot Awards shows that, by working together closely, we succeeded in developing devices with a unique design and high user friendliness that inspire confidence and convey responsibility.”
With their clear and functional product design language, the pens ranked first amongst tough competition for a Red Dot Award, which is celebrating its 60th anniversary. The Red Dot Awards will be presented at a gala in Essen, Germany, on 29 June 2015.